Recombinant erythropoietin in clinical practice

Postgraduate Medical Journal

Volumn 79, Issue 933, 2003, Pages 367-376

  Ng, Thomas ^a   Marx, G ^b   Littlewood, T ^c   Macdougall, I ^d  

^a Phase I Clinical Trials Unit   (United Kingdom)

^b Sydney Haematology Oncology Clinic   (Australia)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CARNITINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GROWTH FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 3; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; SOMATOMEDIN; ZIDOVUDINE;

ALLERGIC REACTION; AMINO ACID SEQUENCE; ANAPHYLAXIS; ANEMIA; ATHLETE; AUTOIMMUNE DISEASE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; CRITICAL ILLNESS; DIALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ABUSE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PURIFICATION; DRUG RESPONSE; DRUG SCREENING; DRUG STRUCTURE; DRUG UTILIZATION; FLU LIKE SYNDROME; GENETIC ANALYSIS; GRAFT REJECTION; HEALTH CARE COST; HEMATOLOGIC DISEASE; HEMOLYSIS; HISTORY OF MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERKALEMIA; HYPERTENSION; KIDNEY GRAFT; NEUROPROTECTION; PERIOPERATIVE PERIOD; PRELEUKEMIA; PREMATURITY; PURE RED CELL ANEMIA; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SEQUENCE ANALYSIS; SIDE EFFECT; SOLID TUMOR; STEM CELL TRANSPLANTATION; STRUCTURE ANALYSIS; THROMBOCYTOSIS; THROMBOSIS;

ANEMIA; BLOOD TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 0041660591     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.79.933.367     Document Type: Review

References (102)

1. Jelkmann W. Erythropoietin: structure, control of production and function. Physiol Rev 1992;72:449-89.
2. Winearls CG, Oliver DO, Pippard MJ, et al. Effects of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;ii:1775-8.
3. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anaemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-8.
4. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patient with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992-1000.
5. Law ML, Cai GY, Lin FK, et al. Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism. Proc Natl Acad Sci U S A 1986;83:6920-4.
6. Inoue N, Takeuchi M, Ohashi H, et al. The production of recombinant human erythropoietin. Biotechnology Annual Review 1995;1:297-313.
7. Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16(suppl 3):14-21.
8. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for the treatment of anaemia in chronic renal insufficiency. Kidney Int 2001;60;2:741-7.
9. Glaspy J, Jadeja JS, Justice G, et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 2001;84(suppl 1):17-23.
10. Smith RE Jr, Jaiyesimi IA, Meza LA, et al. Novel erythropoietic stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer 2001;84(suppl 1):24-30.
11. Silva M, Grillot D, Benito A, et al. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 1996;88:1576-82.
12. Huraib S, Abu-Aisha H, al-Momen A, et al. Effect of recombinant human erythropoietin on lymphocyte phenotyping and phagocyte activity in hemodialysis patients. Am J Kidney Dis 1997;29:866-70.
13. Tilbrook PA, Klinken SP. The erythropoietin receptor. Int J Biochem Cell Biol 1999;31:1001-5.
14. Macdougall IC. Meeting the challenges of: a new millennium: optimising the use of recombinant human erythropoietin. Nephrol Dial Transplant 1998;13(suppl 2):23-7.
15. Johnson CA, Wakeen M, Taylor CA, et al. Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients. Perit Dial Int 1999;19:578-82.
16. Deputy Chief Medical Officer. Eprex® (epoetin alfa) and pure red cell aplasia - contraindication of subcutaneous administration to patients with chronic renal disease. London: Medical Control Agency, December 2002.
17. Eschbach JW. Erythropoietin: the promise and the facts. Kidney Int 1994;45(suppl 44):S70-6.
18. Mocks J. Cardiovascurar mortality in haemodialysis patients treated with epoetin beta - a retrospective study. Nephron 2000;86:455-62.
19. Silverberg J, Rahal D, Pattin R, et al. Role of anaemia in the pathogenesis of left ventricular hypertrophy in end stage renal disease. Am J Cardiol 1989;64:222-4.
20. Muirhead N, Bargman J, Burgess E et al. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 1995;26(suppl 1):S1-24.
21. Jungers P, Choukroun G, Oualim Z, et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001;16:307-12.
22. Cody J, Daly C, Campbell M, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients (Cochrane review). Cochrane Database System Review 2001;4:CD003266.
23. Eknoyan G. The importance of early treatment of anemia of chronic kidney disease. Nephrol Dial Transplant 2001;16(suppl 5):45-9.
24. Silverberg DS, Blum M, Agbaria Z, et al. The effect of iv iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol 2001;55:212-9.
25. Chapman JR. Blood transfusion policy. In: Catto GRD, ed. New clinical application nephrology: transplantation. London: Kluwer Academic Publication, 1989: 1-38.
26. Zaoui P, Boyle F, Mayrizi J, et al. Early thrombosis in kidney grafted into patients treated with erythropoietin. Lancet 1988;ii:956.
27. Wahlberg J, Jacobsson J, Odlind B, et al. Hemodilution in renal transplantation in patients on eryhtropoietin. Lancet 1988;ii:1418.
28. Muirhead N. Erythropoietin and renal transplantation. Kidney Int 1999;69(suppl):86-92.
29. Linde T, Ekberg H, Forslund T, et al. The use of pretransplant erythropoietin to normalise hemoglobin level: no deleterious effects on renal transplantation outcome. Transplantation 2001;71:79-82.
30. Strauss RG. Erythropoietin and neonatal anaemia. N Engl J Med 1994;330:1227-8.
31. Obladen M, Maier RF. Recombinant erythropoietin for prevention of anaemia in pre- term infants. Journal of Perinatal Medicine 1995;23:119-26.
32. Reiter PD, Rosenberg AA, Valuck RJ. Factors associated with successful epoetin alfa therapy in premature infants. Ann Pharmacother 2000;34:433-9.
33. Franz AR, Pohlandt F. Red blood cell transfusions in very and extremely low birthweight infants under restrictive transfusion guidelines: is exogenous erythropoietin necessary? Arch Dis Child Fetal Neonatal Ed 2001;84:F96-100.
34. Meyer MP. Anaemia of prematurity. Epidemiology, management and costs. Pharmacoeconomics 1997;12:438-45.
35. Schefels J, Merz U, Hornchen H. Die Prophylaxe der Fruhgeborenenanamie mit rekombinantem humanen Erythropoietin: eine Kosten-Nutzen-analyse. Z Geburtshilfe Neonatal 1999;203(suppl 2):1-5.
36. Ledbetter DJ, Juul SE. Erythropoieitn and the incidence of necrotising enterocolitis in infants with very low birth weight. J Pediatr Surg 2000;35:178-87.
37. Griffiths G, Lall R, Chatfield S, et al. Randomised controlled double blind study of role of recombinant erythropoietin in the prevention of chronic lung disease. Arch Dis Child Fetal Neonatal Ed 1997;76:F190-2.
38. Soubasi V, Kremenopoulos G, Tsantali C, et al. Use of erythropoietin and its effect on blood lactate and 2,3-diphosphoglycerate in premature neonates. Biol Neonate 2000;78:281-7.
39. Spivak JL. Recombinant human erythropoietin and the anaemia of cancer. Blood 1994;84:997-1004.
40. Hamasaki N, Yamamoto M. Red blood cell function and blood storage. Vox Sang 2000;79:191-7.
41. van Bommel J, de Korte D, Lind A, et al. The effect of the transfusion of stored RBCs on intestinal microvascular oxygenation in the rat. Transfusion 2001;41:1515-23.
42. Fernandes CJ Jr, Akamine N, de Marco FVC, et al. Red blood cell transfusion does not increase oxygen consumption in critically ill septic patients. Crit Care 2001;5:362-7.
43. Regan FA, Hewitt P, Barbara JA, et al. Prospective investigation of transfusion transmitted infection recipients of over 200,000 units of blood. TTI Study Group. BMJ 2000;320:403-6.
44. McCullough J. Complications of transfusion. In: McCullough J, ed. Transfusion medicine. New York: McGraw-Hill, 1998: 337-60.
45. Vamvakas EC. Allogeneic blood transfusion as a risk factor for the subsequent development of non-Hodgkin's lymphoma. Transfus Med Rev 2000;14:258-68.
46. Beatty C. Autologous transfusion. In: Murphy MF, Pamphilon DH, eds. Practical transfusion medicine. UK: Blackwell Science, 2001: 263-75.
47. Roback JD. CMV and blood transfusion. Reviews in Medical Virology 2002;12:211-9.
48. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-92.
49. Mittelman M, Neumann D, Peled A, et al. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A 2001;98:5181-6.
50. Case DC Jr, Bukonski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemia cancer patients on combination therapy. J Natl Cancer Inst 1993;85:801-6.
51. Casinu S, Fedeli A, Del Ferro E, et al. Recombinant human erythropoietin in cisplatin-associated anemia: a randomised, double-blinded trial with placebo. J Clin Oncol 1994;12:1058-62.
52. Del Mastro L, Venturini M, Lionetoo R, et al. Randomised phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997;15:2715-21.
53. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, et al. Controlled multicenter study of the influence of subcutaneous recombinant erythropoietin on anemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998;15:174-82.
54. Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer related or chemotherapy-induced anemia in patients with solid tumors. Med Oncol 1998;15(suppl 1):S19-28.
55. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin-alfa is independent of disease response or tumor type results from a prospective community oncology study, Procrit Study Group. J Clin Oncol 1998;16:3412-25.
56. Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001;28(2 suppl 8):49-53.
57. Antonadou D, Cardamakis E, Puglisi M, et al. Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomised phase III study. Eur J Cancer 2001;37(suppl 6):144.
58. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in haemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-95.
59. Rose E, Rai K, Revicki D, et al. Clinical and health states assessment in anemic chronic lymphatic leukaemia (CLL) patients treated with epoetin alfa (epo). Journal of the American Society of Hematology 1994;84:526a.
60. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of the predictors of response. Blood 1995;86:4446-53.
61. Osterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoieitn in transfusion-dependent anaemic patients with multiple myeloma and non-Hodgkin's lymphoma-a randomised multicentre study. Blood 1996;87:2675-82.
62. Dammaco F, Silvestris F, Castoldi GL, et al. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotheropy. Int J Clin Lab Res 1998;28:127-34.
63. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndrome: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:67-71.
64. Hellstrom-Lindberg E, Negria R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anemia of patients with myelodysplastic syndrome: proposals of a predictive model. Br J Haematol 1997;99:344-51.
65. Hast R, Wallvik J, Folin A. Long-term follow-up of 18 patients with myelodysplastic syndrome responding to recombinant erythropoietin treatment. Leuk Res 1999;25:13-8.
66. Pihlstedt P, Paulin T, Sundberg B, et al. Blood transfusion in marrow graft recipients. Ann Hematol 1992;65:66-70.
67. Klaesson S. Clinical use of rHuEPO in bone marrow transplantation. Med Oncol 1999;16:2-7.
68. McCullough J. Autologous blood donation and transfusion. In: McCullough J, ed. Transfusion medicine. New York: McGraw-Hill, Health Professions Division, 1998: 99-118.
69. Yazicioglu L, Eryilmaz S, Sirlak M, et al. Recombinant human erythropoietin administration in cardiac surgery. J Cardiothorac Surg 2001;122:741-5.
70. Stovall TG. Clinical experience with epoetin alfa in the management of hemoglobin levels in orthopedic surgery and cancer. Implication for use in gynecologic surgery. J Reprod Med 2001;46(5 suppl):531-8.
71. Wurnig C, Schatz K, Noske H, et al. Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation. Eur Surg Res 2001;33:303-10.
72. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infections and zidovudine therapy. Overview of four clinical trials. Ann Intern Med 1992;117:739-48.
73. Phair JP, Abels RI, McNeill MV, et al. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Arch Intern Med 1993;153:2669-75.
74. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:29-33.
75. Volberding P. Consensus statement: anemia in HIV infection-current trend in treatment options, and practice strategies. Anemia in HIV Working Group. Clin Ther 2000;22:1004-20.
76. Peeters HR, Jongen-Lavrencic M, Bakkar CH, et al. Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatol Int 1999;18:201-6.
77. Linardaki GD, Boki KA, Fertakis A, et al. Pure red cell aplasia as presentation of systemic lupus erythematosus:antibodies to erythropoietin. Scand J Rheumatol 1999;28:189-91.
78. Christodoulou DK, Tsianos EV. Anemia in inflammatory bowel disease - the role of recombinant erythropoietin. European Journal of Internal Medicine 2000;11:222-7.
79. Tchernia G, Delhommeau F, Perrotta S, et al. Recombinant erythropoietin therapy as an alternative to blood transfusion in infants with hereditary spherocytosis. Hematology Journal 2000;1:146-52.
80. Shapira Y, Bairey O, Vatury M, et al. Erythropoieitin can obviate the need for repeated heart valve replacement in high-risk patients with severe mechanical haemolytic anemia: case reports and literature review. J Heart Valve Dis 2001;10:431-5.
81. Rachmilewitz EA, Aker M. The role of recombinant human erythropoietin in the treatment of thalassemia. Ann N Y Acad Sci 1998;850:129-38.
82. Nemoto T, Yokota N, Keane WF, et al. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int 2001;59:246-51.
83. Westenfelder C. Unexpected renal actions of erythropoietin. Exp Nephrol 2002;10:294-8.
84. Bagnis C, Beaufils H, Jacquiaud C, et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 2001;16:932-8.
85. Kurt E, Evrensel T, Dilek K, et al. Effects of two different doses of recombinant human erythropoietin (r-HuEPO) on cisplatin-induced acute renal failure. Proceedings of the American Society of Clinical Oncology 2002 (abst 1842).
86. van Iperen CE, Gaillard CA, Kraaijenhagen RJ, et al. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000;28:2773-8.
87. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patients: a randomised, double-blind, placebo-controlled trial. Crit Care Med 1999;27:2346-50.
88. Cerami A. Beyond erythropoiesis: novel applications for recombinant human erythropoietin. Semin Hematol 2001;38(3 suppl 7):33-9.
89. Gorio A, Gokmen N, Erbayraktar S, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery experimental spinal cord trauma. Proc Natl Acad Sci U S A 2002;99:9450-5.
90. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.
91. Silverberg DS, Wexler D, Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. European Journal of Heart Failure 2002;4:681-6.
92. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetes and non-diabetes with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-6.
93. Robinson A, ed. Blood matters. Quarterly information for hospitals served by the National Blood Service. UK: National Blood Service, September 2001 (issue 8).
94. Chikada M, Furuse A, Kotsuka Y, et al. Open-heart surgery in Jehovah's Witness patients. Cardiovasc Surg 1996;4:311-4.
95. Nelson CL, Stewart JG. Primary and revision total hip replacement in patients who are Jehovah's Witnesses. Clin Orthop 1999;369:251-61.
96. Busuttil D, Copplestone A. Management of blood loss in Jehovah's Witnesses. BMJ 1995;311:1115-6.
97. Ekblom BT. Blood boosting and sport. Baillieres Clin Endocrinol Metab 2000;14:89-98.
98. Bolanos L, Castro P, Falcon TG, et al. Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients. Am J Nephrol 2002;22:67-72.
99. Casadevall N, Natal J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75.
100. Gershon SK, Luksenburg H, Cote TR, et al. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002;346:1584-5.
101. Casadevall N, Mayeux P. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002;346:1585.
102. Casadevall N. Antibodies against r-HuEPO: native and recombinant. Nephrol Dial Transplant 2002;17(suppl 5):42-7.